1 |
Ross PJ, Teoh EM, A'hern RP, Rhys-Evans PH, Harrington KJ, Nutting CM, et al. Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma. Clin Oncol (R Coll Radiol) 2009;21(4): 311-4.
DOI
ScienceOn
|
2 |
Dahse R, Driemel O, Schwarz S, Dahse J, Kromeyer-Hauschild K, Berndt A, et al. Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer 2009;100:623-5.
DOI
ScienceOn
|
3 |
Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002; 54:1180-93.
DOI
ScienceOn
|
4 |
Bonner JA, Giralt J, Harari PM, Cohen R, Jones C, Sur RK, et al. Prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high does radiation therapy with and without cetuximab. J Clin Oncol 2004;22:5507.
DOI
|
5 |
Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004;11:689-708.
DOI
ScienceOn
|
6 |
Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984;259:7755-60.
|
7 |
Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003.
|
8 |
Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004;108:464-72.
DOI
ScienceOn
|
9 |
Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 2006;12:600-7.
DOI
ScienceOn
|
10 |
Raynal C, Pascussi JM, Leguelinel G, Breuker C, Kantar J, Lallemant B, et al. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer 2010; 9:46.
|
11 |
Louvet C, Andre T, Gamelin E, Garcia ML, Saavedra A, Lenaers G, et al. A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT-11) in previously pretreated metastatic colorectal cancer patients. Bull Cancer 2004;91:279-84.
|
12 |
Kokawa K, Nishimura R, Fujii T, Umesaki N. Neoadjuvant chemotherapy with irinotecan and mitomycin-C for locally advanced squamous cell carcinoma of the uterine cervix. Anticancer Res 2007;27:2721-7.
|
13 |
Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M, Shapiro CL. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Ann Oncol 2008;19:1417-22.
DOI
ScienceOn
|
14 |
Argiris A, Buchanan A, Brockstein B, Kolesar J, Ghebremichael M, Pins M, et al. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer 2009;115:4504-13.
DOI
ScienceOn
|
15 |
Bastos BR, Hatoum GF, Walker GR, Tolba K, Takita C, Gomez J, et al. Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cell lung cancer. J Thorac Oncol 2010;5(4):533-9.
DOI
ScienceOn
|
16 |
Ciardiello F, Bianco R, Damiano V, de Lorenzo S, Pepe S, de Placido S, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909-16.
|
17 |
Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-40.
|
18 |
Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007;25:3978-84.
DOI
ScienceOn
|
19 |
Dahse R, Driemel O, Schwarz S, Kromeyer-Hauschild K, Berndt A, Kosmehl H, et al. KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. Oral Oncol 2009;45:826-9.
DOI
ScienceOn
|
20 |
Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997;8:837-55.
DOI
ScienceOn
|
21 |
Rivory LP. Irinotecan (CPT-11): a brief overview. Clin Exp Pharmacol Physiol 1996;23:1000-4.
DOI
ScienceOn
|
22 |
Larsen AK, Gobert C. DNA topoisomerase I in oncology: Dr. Jekyll or Mr. Hyde? Pathol Oncol Res 1999;5:171-8.
DOI
ScienceOn
|
23 |
Saijo N. Preclinical and clinical trials of topoisomerase inhibitors. Ann N Y Acad Sci 2000;922:92-9.
|
24 |
Friedman HS, Keir ST, Houghton PJ. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer 2003;97(9 Suppl):2359-62.
DOI
ScienceOn
|
25 |
Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-95.
DOI
ScienceOn
|
26 |
Park YW, Chung SH. An experimental study for establishment of orthotopic salivary tumor models in mice. J Korean Assoc Oral Maxillofac Surg 2007;33:81-93.
과학기술학회마을
|
27 |
Park YW. Targeted molecular therapy in a murine model of oral squamous cell carcinoma with an epidermal growth factor receptor inhibitor. J Korean Assoc Maxillofac Plast Reconstr Surg 2009;31:8-17.
과학기술학회마을
|
28 |
Licitra L, Locati LD, Bossi P, Cantu G. Head and neck tumors other than squamous cell carcinoma. Curr Opin Oncol 2004; 236-41.
DOI
ScienceOn
|
29 |
Jones AS, Hamilton JW, Rowley H, Husband D, Helliwell TR. Adenoid cystic carcinoma of the head and neck. Clin Otolaryngol 1997;22:434-43.
DOI
ScienceOn
|
30 |
Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary grand cancers. J Clin Oncol 2006; 24:2673-8.
DOI
ScienceOn
|
31 |
Airoldi M, Cortesina G, Giordano C, Pedani F, Cavalot A, Marcato P, et al. Update and perspectives on non-surgical treatment of salivary gland malignancies. Acta Otorhinolaryngol Ital 2003;23:368-76.
|
32 |
Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fan D, Villares GJ, et al. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia 2008;10:489-500.
DOI
|
33 |
Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol 2002; 29(5 Suppl 14):18-30.
DOI
|
34 |
Park YW, Kim JH. Immunohistochemical assays for the expression of epidermal growth factor-signaling proteins in adenoid cystic carcinoma of human salivary glands. J Korean Assoc Maxillofac Plast Reconstr Surg 2006;28:499-510.
과학기술학회마을
|
35 |
Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, et al. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther 2006;5:2696-705.
DOI
ScienceOn
|